Product logins

Find logins to all Clarivate products below.


Major Depressive Disorder (DSM-V) – Epidemiology – Epidemiology – Major Depressive Disorder (DSM V) – Mature Markets

Clarivate Epidemiology’s coverage of major depressive disorder (MDD) (DSM-V) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets. We report the prevalence of MDD (DSM-V) for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s MDD (DSM-V) forecast will answer the following questions:

  • Of all people with MDD (DSM-V), how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with MDD (DSM-V), how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MDD (DSM-V) over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology forecasts the following MDD (DSM-V) patient populations:

  • Total lifetime prevalent cases.
  • Total 12-month prevalent cases.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Bipolar Disorder – Current Treatment – Current Treatment: Physician Insights – Bipolar Disorder (EU5)
Bipolar disorder (BD) is a spectrum disorder characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Lithium…
Report
Eosinophilic Esophagitis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of eosinophilic esophagitis (EoE) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States…
Report
Gout – Epidemiology – Middle East & Africa
Clarivate Epidemiology’s coverage of gout comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of gout for each country, as well as…
Report
Gout – Epidemiology – Asia Pacific
Clarivate Epidemiology’s coverage of gout comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of gout for each country, as well as…
Report
Gout – Epidemiology – Americas
Clarivate Epidemiology’s coverage of gout comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of gout for each country, as well as…